Effectiveness and safety of Pegylated-Interferon/Ribavirin and direct acting antiretroviral: DAA treatment in chronic hepatitis C in Chiangrai Prachanukroh hospital
Article Sidebar
Main Article Content
Abstract
Effectiveness and safety of Pegylated-Interferon/Ribavirin and direct acting antiretroviral: DAA treatment in chronic hepatitis C in Chiangrai Prachanukroh hospital
Chotipong Siripipattanamongkol, MD. Chiangrai Prachanukroh hospital
Chanagune Srinarong, MD. Chiangrai Prachanukroh hospital
Patchareeya Asa, Chiangrai Prachanukroh hospital
Abstract
Objective: Chronic hepatitis C is the major liver disease in Chiangrai, without treatment it will lead to cirrhosis, liver cancer and death. Curative treatment for Chronic hepatitis C was available in Chiangrai Prachanukroh hospital since 2014. Effectiveness and safety of Pegylated-Interferon/Ribavirin and direct acting antiretroviral: DAA was investigated
Method: This retrospective cohort study was enrolled adult Chronic hepatitis C patient who underwent treatment between 2014, January to 2017, December, baseline characteristic, co-morbidity, HCV-data, treatment regimen, outcomes and adverse effects were collected using electronic database. Proper statistic methods were warranted.
Result: 201 patients were enrolled, 179 patients have complete data for analysis. Mean age was 47.5±9.12 years, 60.3% were male, 50.28% were co-infected with HIV, 49.7% found cirrhosis, 94% were naïve for treatment, HCV genotype 1a(25.7%), 1b(12.8%), 3(42.5%) and 6(18.99%) ,median HCV viral load was 5.95(5.34,6.35)log10 unit/ml. Treated with Pegylated interferon+ribavirin 58.6% and DAA 41.3%. Sustained virologic response (SVR) was achieved in 140(78.77%) patients, relapse 18(10%), null response (6.7%), lost to follow up 3(1.68%), in-tolerate to side effects 3(1.68%) and death 2(1.12%). Highest adverse effect was anemia 29.9%, 2 cases complicated with acute renal failure. Hyperthyroidism, hepatocellular carcinoma, gastrointestinal stromal tumor was found in 3 individuals respectively, multivariable analysis showed non-HIV status, HCV genotype 3, WBC count<6,000 cells/mm3, younger age, lower BMI and higher doses of ribavirin are positive association with SVR
Conclusion: Treatment for chronic hepatitis C in Chiangrai Prachanukroh hospital is effective and acceptable safety profile.
Keyword: HCV, Chiangrai, treatment, outcome, safety
Article Details
References
2. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012 Dec 26;308(24):2584-93.
3.Zhou J, Dore GJ, Zhang F et al. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007; 22: 1510-8.
4.Sungkanuparph S, Vibhagool A, Manosuthi W et al. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. J Med Assoc Thai 2004; 87: 1349-54.
5.Bruno S, Maisonneuve P. Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population". J Hepatol. 2017 Apr 20.
6.Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015 Jan;61(1):77-87.
7.Garten RJ, Zhang J, Lai S et al. Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis 2005; 41 Suppl 1: S18-24.
8.รายงานจากกองระบาดวิทยาปี พ.ศ. 2551. Annual Epidemiological Surveillance Report 2008, ISSN 0857-6521. http://epid.moph.go.th
9.AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases, Volume 67, Issue 10, 15 November 2018, Pages 1477–1492, https://doi.org/10.1093/cid/ciy585
10.European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015, J Hepatol. 2017 Jan;66(1):153-194.
11.Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
12.Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.
13.Mohsen AH, Easterbrook PJ, Taylor C et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52: 1035-40.
14.Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
15.Puoti M, Bruno R, Soriano V et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18: 2285-93.
16.Amin J, Kaye M, Skidmore S et al. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004; 5: 174-9.
17.Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002.
18.Law WP, Dore GJ, Duncombe CJ et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. Aids 2003; 17: 2191-9.
19.Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-13.
20.Chung RT, Andersen J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
21.Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
22.Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-51.
23.Wasitthankasem R, Vongpunsawad S, Siripon N, Suya C, Chulothok P, Chaiear K, et al. Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia. PLoS One. 2015;10(5):e0126764.
24.Kanistanon D, Neelamek M, Dharakul T et al. Genotypic distribution of hepatitis C virus in different regions of Thailand. J Clin Microbiol 1997; 35: 1772-6.
25.เสรีภาพ แซ่อึ้ง. ผลการรักษาผู้ป่วยไวรัสตับอักเสบซีด้วยสูตรยา Pegylated interferon และ ribavirin ในโรงพยาบาลสุราษฏร์ธานี 2556-2558. วารสารวิชาการแพทย์เขต 11 ปีที่ 31 ฉบับที่ 2 เม.ย.- มิ.ย. 2560:223-233
26.Smolders EJ, Thammajaruk N, de Kanter CTMM, Colbers A, Chaiyahong P, Cuprasitrut T, Chittmittraprap S, Apornpong T, Khemnark S, Tangkijvanich P, Burger DM, Avihingsanon A. Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics.Trop Med Int Health. 2018 Mar;23(3):295-305.
27.Watcharasak Chotiyaputta. Uayporn Kaosombatwattana. N. Chamroonkul. Chalermrat Bunchorntavakul. K. Seansawat Efficacy of pegylated interferon and ribavirin for the treatment of chronic hepatitis C, genotype 3 patients in Thailand. J Med Assoc Thai 2018; 101(4):127
